Skip to main content

Table 2 Characteristics compared between those with and without metabolic syndrome further compared among all included patients, ankylosing spondylitis patients, and psoriatic arthritis patients

From: Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study

Characteristics

All

(n = 319)

Ankylosing spondylitis

(n = 153)

Psoriatic arthritis

(n = 166)

Metabolic syndrome

Metabolic syndrome

Metabolic syndrome

Yes

(n = 101)

No

(n = 218)

Yes

(n = 29)

No

(n = 124)

Yes

(n = 72)

No

(n = 94)

Number of MetS criteria, median (IQR)

4.0 (1.0)

1.0 (2.0)*

4.0 (1.0)

1.0 (2.0)*

3.5 (1.0)

1.0(2.0)*

Elevated WC, n (%)

93 (92.1%)

60 (27.5%)*

24 (82.8%)

34 (27.4%)*

69 (95.8%)

26 (27.7%)*

Elevated BP, n (%)

87 (86.1%)

55 (25.2%)*

24 (82.8%)

28 (22.6%)*

63 (87.5%)

27 (28.7%)*

Elevated FG, n (%)

74 (73.3%)

38 (17.4%)*

23 (79.3%)

13 (10.5%)*

51 (70.8%)

25 (26.6%)*

Elevated TG, n (%)

50 (49.5%)

20 (9.2%)*

12 (41.4%)

12 (9.7%)*

38 (52.8%)

8 (8.5%)*

Reduced HDL-C, n (%)

63 (62.4%)

26 (11.9%)*

21 (72.4%)

12(9.7%)*

42 (58.3%)

14 (14.9%)*

Age (yrs), mean ± SD

52.3 ± 10.1

42.3 ± 11.9*

48.0 ± 9.2

40.3 ± 11.2*

54.0 ± 9.9

45.1 ± 12.3*

Female gender, n (%)

55 (54.5%)

93 (42.7%)*

8 (27.6%)

51 (41.1%)

47 (65.3%)

42 (44.7%)*

History of smoking, n (%)

13 (12.9%)

42 (19.3%)

4 (13.8%)

18 (14.5%)

9 (12.5%)

24 (25.5%)*

Current smoker, n (%)

5 (5.0%)

22 (10.1%)

3 (10.3%)

9 (7.3%)

2 (2.8%)

13 (13.8%)*

Current exercise, n (%)

40 (39.6%)

94 (43.1%)

9 (31.0%)

40 (49.2%)

31 (43.1%)

33 (35.1%)

Physical work, n (%)

37 (36.6%)

85 (39.0%)

8 (27.6%)

41 (33.1%)

29 (40.3%)

44 (46.8%)

BMI (kg/m2), mean ± SD

27.2 ± 6.0

23.1 ± 4.5*

27.0 ± 4.5

22.5 ± 4.6*

27.3 ± 4.5

23.7 ± 4.3*

Disease duration (yrs), median (IQR)

5.0 (8.0)

5.0 (9.0)

10.0(14.5)

10(13.8)

3.0(6.5)

3.0(4.6)

ASDAS-CRP, mean (SD)

2.0 (1.1)

2.2 (1.1)

2.0 (1.1)

2.2(1.1)

2.0 (1.1)

2.3 (1.2)

DAPSA, median (IQR)

N/A

N/A

N/A

N/A

6.3 (10.5)

9.1 (12)

cDAPSA, median (IQR)

N/A

N/A

N/A

N/A

6.0(9.5)

8.0 (11)

No. of SynAnk, median (IQR)

5.5 (8.0)

2.0 (7.0)*

5.0 (11.5)

2.0 (10.0)*

6.0 (9.0)

2.0 (5.0)*

Current DMARDs, median (IQR)

1.0 (1.5)

1.0 (0)

1.0 (1.5)

1.0 (1.0)

1.0 (1.0)

1.0 (0.25)

Current NSAIDs, n (%)

34 (33.7%)

81 (37.2%)

12 (41.3%)

53 (42.7%)

22 (30.6%)

28 (29.8%)

  1. *Indicates a p-value< 0.05
  2. Abbreviations: MetS Metabolic syndrome; IQR Interquartile range; WC Waist circumference; BP Blood pressure; FG Fasting glucose; TG Triglycerides; HDL-C High-density lipoprotein cholesterol; SD Standard deviation; BMI Body mass index; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; cDAPSA Clinical Disease Activity Index for Psoriatic Arthritis; DAPSA Disease Activity Index for Psoriatic Arthritis; SynAnk Syndesmophyte or ankylosis; DMARDs Disease modifying antirheumatic drugs; NSAIDs Non-steroidal anti-inflammatory drugs, N/A Not applicable